Getting to the Mutations | GenomeWeb

Sequencing of tumors and drugs targeted to mutations found in those cancers are beginning to change how cancer is treated, the Wall Street Journal reports.

The newspaper focuses on Kellie Carey, a lung cancer patient who was given a few months to live back in 2010. But through persistence, Carey persuaded her physicians to genotype her tumor, and they uncovered that she had an ALK gene mutation that could be targeted by Pfizer's Xalkori.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

Target: BRAF V600

Just a Pinprick

Between the Coasts

The Pair of Them

The Next Step

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.